No pain, no gain: Warner-Lambert v Actavis preview


Arty Rajendra

No pain, no gain: Warner-Lambert v Actavis preview

maradonna 8888 /

The English Court of Appeal has issued the latest ruling in the patent dispute between Warner-Lambert and Actavis concerning Lyrica (pregabalin), says Arty Rajendra of Rouse Legal.

At 10:30am on June 29, a London court room packed full of patent lawyers will fall silent as the trial in Warner-Lambert v Actavis commences.

This case has already attracted significant media attention because it will determine how generic manufacturers market drugs for which the primary patent protection has expired but a second medical use patent for the drug remains valid.

Warner-Lambert, owned by pharmaceutical company Pfizer, markets the drug pregabalin under the brand name Lyrica.

Warner-Lambert, Actavis, patent, patent infringement, medical use, pregabalin,